Strong uptake puts pressure on Lenacapavir stocks
South Africa’s twice-yearly HIV-prevention injection has drawn strong interest, but limited supplies and high costs threaten to slow its expansion beyond the first six provinces.
This story was published by IOL. Read the full article on their site.
Read the full story at iol.co.za(opens in a new tab)




